Recombinant Human Lecithin retinol acyltransferase (LRAT)-VLPs

What is the fundamental biochemical function of LRAT in human physiology?

LRAT (Lecithin retinol acyltransferase) catalyzes the reversible esterification of vitamin A (all-trans-retinol) using phosphatidylcholine (PC) as the acyl donor. Specifically, LRAT transfers the fatty acid from the sn-1 position of phosphatidylcholine to all-trans-retinol, creating fatty acid retinyl esters (predominantly palmitoyl, stearoyl, and some unsaturated derivatives) . This 25.3 kDa enzyme is critical for both vitamin A storage and a key reaction in the retinoid cycle. Unlike other acyltransferases, LRAT does not require activation of fatty acyl groups attached to coenzyme A via thioester bonds .

Which catalytic residues are essential for LRAT activity and how do they function in the enzymatic mechanism?

LRAT contains a catalytic dyad consisting of Cys161 and His60 residues that are essential for its enzymatic activity . These residues function in a mechanism reminiscent of thiol proteases, yet the local primary sequence contexts of C161 and H60 are not homologous to those found in the approximately 20 known thiol protease families . LRAT employs a double-displacement reaction mechanism in which the catalytic cysteine residue becomes acylated and subsequently transfers the acyl intermediate to retinol, creating retinyl esters .

How does the structure of LRAT relate to its function in the context of VLP development?

Recent crystallographic data have revealed that LRAT functions through a domain-swapping mechanism involving homodimerization. The structure displays two globular catalytic domains separated by a pair of three-stranded antiparallel β strands . This domain-swapping is crucial for LRAT's sn-1 regiospecificity for the PC acyl donor that produces esters with retinol . When developing LRAT-VLPs, researchers must consider this structural characteristic to ensure proper protein folding and enzymatic activity within the VLP context.

What expression systems are most effective for producing functional recombinant human LRAT for VLP development?

For functional expression of recombinant human LRAT, adenoviral vector systems have been proven effective. Researchers have successfully cloned rat LRAT cDNA through reverse transcription of RNA extracts from primary rat hepatic stellate cells (HSCs), using specific primers with restriction enzyme recognition sites (e.g., BamHI and EcoRI) . The PCR product can be cloned into an adenoviral vector (e.g., pAd/CMV/VS-DEST) followed by sequencing confirmation . For human LRAT, a similar approach can be employed using human-specific primers and appropriate expression systems.

When expressing LRAT for VLP development, the following protocol has been effective:

• Clone human LRAT cDNA using RT-PCR from human RPE or liver cells

• Insert the coding sequence into an appropriate vector with a strong promoter

• Transfect/transduce mammalian cells (e.g., 293A cells)

• Purify the recombinant protein using affinity chromatography

• Assemble VLPs under optimized conditions considering LRAT's dimerization properties

What methodological approaches can be used to verify the enzymatic activity of recombinant LRAT within VLP structures?

To verify enzymatic activity of LRAT within VLPs, researchers should employ multiple complementary approaches:

• Spectrophotometric/fluorometric assays: Measure the formation of retinyl esters from all-trans-retinol and phosphatidylcholine

• LC/MS/MS analysis: Quantitatively determine the amount of retinyl palmitate (the dominant form of stored retinoids) produced by the LRAT-VLPs

• Western blot analysis: Confirm LRAT protein expression using monoclonal antibodies against LRAT

• Oil red O staining: Visualize the formation of lipid droplets when cells are treated with retinol and palmitate, indicating functional esterification activity

• Auto-fluorescence measurements: Assess retinoid content through UV excitation, as retinoids emit auto-fluorescence

How can researchers optimize LRAT-VLP stability without compromising enzymatic function?

Maintaining LRAT-VLP stability while preserving enzymatic function requires careful consideration of several factors:

• Buffer composition: Use buffers containing appropriate pH (7.0-7.5) and ionic strength

• Lipid composition: Include phospholipids similar to those found in native environments where LRAT functions

• Storage conditions: Store at -80°C with cryoprotectants or lyophilize for long-term storage

• Dimerization preservation: Ensure conditions maintain the native dimeric state of LRAT, as domain swapping is essential for function

• Antioxidant addition: Include antioxidants to prevent oxidation of critical cysteine residues (especially C161)

For experimental verification of stability, researchers should assess activity at different time points and storage conditions, along with structural integrity via techniques like circular dichroism spectroscopy.

How can LRAT-VLPs be utilized to model retinal diseases associated with LRAT mutations?

LRAT mutations are responsible for approximately 1% of Leber congenital amaurosis (LCA) cases, a rare hereditary retinal dystrophy with early onset . LRAT-VLPs can serve as valuable tools for modeling these diseases:

• Structure-function studies: Incorporate disease-causing mutations into recombinant LRAT within VLPs to study their effects on enzyme structure and function

• High-throughput screening: Use LRAT-VLPs with disease mutations to screen for compounds that might rescue enzymatic activity

• Protein-protein interaction studies: Examine how mutations affect interactions with other components of the retinoid cycle

• In vitro disease modeling: Create systems that recapitulate the retinoid cycle using purified components including mutant LRAT-VLPs

• Drug delivery testing: Assess the potential of LRAT-VLPs as carriers for therapeutic agents targeting the retinal pigment epithelium

What strategies can be employed to investigate the interaction between LRAT-VLPs and interleukin-1 signaling in hepatic stellate cells?

Interleukin-1 (IL-1) has been identified as a potent suppressor of LRAT expression in hepatic stellate cells (HSCs), with an IC50 of approximately 0.05 ng/ml . To investigate interactions between LRAT-VLPs and IL-1 signaling, researchers could:

• Competitive binding assays: Determine if LRAT-VLPs compete with endogenous LRAT for regulatory proteins involved in IL-1 signaling

• Transcriptional analysis: Study how LRAT-VLPs affect IL-1-mediated transcriptional regulation of endogenous LRAT

• 3D culture models: Create three-dimensional extracellular matrix cultures of HSCs treated with LRAT-VLPs and IL-1 to simulate the microenvironment in the space of Disse

• Cytokine profiling: Measure changes in cytokine profiles when HSCs are exposed to both IL-1 and LRAT-VLPs

• Retinyl ester mobilization studies: Investigate whether LRAT-VLPs can prevent IL-1-induced mobilization of retinyl esters from HSCs

What are the challenges in designing LRAT-VLPs that can cross the blood-retinal barrier for potential therapeutic applications?

Designing LRAT-VLPs capable of crossing the blood-retinal barrier presents several challenges:

• Size optimization: Standard VLPs (20-200 nm) exceed the typical size limit (≤20 nm) for passive diffusion across the blood-retinal barrier

• Surface modification: Incorporating specific ligands or peptides that facilitate receptor-mediated transcytosis across the barrier

• Charge considerations: Optimizing surface charge to enhance interaction with the barrier while preventing non-specific binding

• Stability in circulation: Ensuring LRAT-VLPs remain intact until reaching the target tissue

• Immune evasion: Designing VLPs to avoid recognition by the immune system

Potential solutions include:

• Incorporating cell-penetrating peptides on the VLP surface

• Using smaller VLP designs (20-30 nm) with higher surface-to-volume ratios

• Attaching targeting moieties specific to transporters expressed at the blood-retinal barrier

• Incorporating PEG or other hydrophilic polymers to extend circulation time and reduce immunogenicity

What advanced imaging techniques are most informative for characterizing the morphology and structural integrity of LRAT-VLPs?

Multiple complementary imaging techniques should be used to fully characterize LRAT-VLPs:

How can researchers distinguish between functional and non-functional conformations of LRAT within VLP structures?

Distinguishing functional from non-functional LRAT conformations within VLPs requires several analytical approaches:

• Site-directed spin labeling with EPR spectroscopy: Monitors the distance between specific residues to confirm proper domain swapping and dimerization

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS): Identifies regions with altered solvent accessibility between functional and non-functional states

• Fluorescence resonance energy transfer (FRET): Measures distances between fluorescently labeled domains to confirm proper structural arrangement

• Limited proteolysis: Functional conformations often have different protease sensitivity patterns compared to non-functional forms

• Correlation of structural data with activity assays: Systematic comparison of structural parameters with enzymatic activity to identify critical structural features

A practical approach would be to introduce cysteine mutations at key positions for site-specific labeling, followed by spectroscopic analysis to confirm the expected distances in the functional dimeric arrangement.

What analytical methods can quantify the incorporation efficiency of LRAT into VLP structures?

To quantify LRAT incorporation efficiency into VLPs, researchers can employ these methods:

• SDS-PAGE with densitometry: Compare protein band intensities between purified VLPs and known quantities of recombinant LRAT

• Western blotting with anti-LRAT antibodies: Perform quantitative immunoblotting using standard curves of purified LRAT

• ELISA: Develop sandwich ELISA using antibodies against both LRAT and VLP structural proteins

• Mass spectrometry-based quantification: Use isotope-labeled standard peptides for absolute quantification of LRAT in VLP preparations

• Enzymatic activity assays: Compare activity per unit protein between free LRAT and LRAT-VLPs to estimate functional incorporation

Additionally, researchers can use analytical ultracentrifugation to determine the protein composition based on sedimentation behavior and density.

How can researchers effectively measure LRAT enzymatic activity within VLP structures compared to free enzyme?

To compare LRAT activity in VLPs versus free enzyme:

• Retinyl ester formation assays: Measure the rate of retinyl ester formation using LC/MS/MS to quantify retinyl palmitate production

• Fluorometric assays: Monitor changes in retinoid auto-fluorescence during enzymatic reactions

• Kinetic parameter determination: Calculate Km and Vmax values for both VLP-associated and free LRAT under identical conditions

• Stability comparisons: Assess activity retention after exposure to various temperatures, pH conditions, and storage durations

• Substrate specificity analysis: Compare the ability of both forms to utilize different retinol analogs and phospholipid sources

Data should be normalized to the amount of LRAT protein present, as determined by quantitative Western blotting or other protein quantification methods .

What are the key considerations when designing experiments to test the effects of IL-1 on LRAT-VLPs compared to endogenous LRAT?

When comparing IL-1 effects on LRAT-VLPs versus endogenous LRAT, researchers should consider:

• Differential regulation mechanisms: Endogenous LRAT is transcriptionally down-regulated by IL-1, while recombinant LRAT in VLPs would not be affected at the transcriptional level

• Concentration-response relationships: Establish concentration-response curves for IL-1 (starting at 0.05 ng/ml, the approximate IC50) for both systems

• Time-course analyses: Monitor changes over time, as endogenous LRAT decreases within 24 hours after IL-1 exposure

• Isolated versus cellular context: Compare effects in cell-free systems versus cellular environments

• Specificity controls: Include other cytokines (TNF-α, TGF-β1, PDGF, IL-6) as comparative controls, as they have different potencies in regulating LRAT

Experimental design should include:

• Primary cell cultures (HSCs or RPE cells)

• Defined medium conditions

• Careful timing of IL-1 addition and sampling

• Multiple readouts (protein levels, enzymatic activity, retinyl ester content)

How can researchers develop high-throughput screening assays using LRAT-VLPs to identify compounds that modulate LRAT activity?

To develop high-throughput screening assays with LRAT-VLPs:

• Fluorescence-based activity assays: Design assays that monitor changes in retinoid fluorescence upon esterification

• Coupled enzyme assays: Develop systems where LRAT activity is linked to a readily detectable signal (fluorescent or colorimetric)

• FRET-based conformational sensors: Engineer LRAT variants with fluorescent proteins that report on conformational changes during catalysis

• Microplate formats: Optimize assay conditions for 384- or 1536-well plate formats

• Automation compatibility: Ensure reagent stability and protocol simplicity for robotic handling

Validation protocols should include:

• Known LRAT inhibitors or activators as positive controls

• DMSO tolerance testing

• Signal-to-background ratio optimization

• Z-factor determination to assess assay quality

• Counter-screening to eliminate false positives

What experimental approaches can assess the potential of LRAT-VLPs as gene therapy vehicles for treating LRAT-associated retinal dystrophies?

To evaluate LRAT-VLPs as gene therapy vehicles:

• In vitro rescue experiments: Test whether LRAT-VLPs can restore retinyl ester formation in cells derived from LRAT-deficient models

• Ex vivo retinal explant studies: Assess the ability of LRAT-VLPs to penetrate retinal layers and restore visual cycle function

• Animal model testing: Evaluate efficacy in LRAT knockout mice, measuring restoration of:

  • Retinyl ester formation in the RPE

  • Visual cycle function

  • Electroretinogram (ERG) responses

  • Prevention of photoreceptor degeneration

• Delivery method optimization: Compare subretinal, intravitreal, and systemic administration routes

• Durability assessments: Determine how long a single treatment maintains therapeutic levels

This approach builds on the proof-of-concept established with recombinant adeno-associated virus (rAAV) vectors incorporating the RPE65 gene, which functions in the same cell type and metabolic pathway as LRAT .

How can researchers reconcile contradicting data between in vitro LRAT-VLP studies and in vivo animal model results?

When facing contradictory results between in vitro LRAT-VLP studies and in vivo models, researchers should:

• Analyze contextual differences:

  • Examine differences in LRAT expression levels between systems

  • Consider the absence of regulatory factors in purified systems

  • Evaluate the influence of the complex retinoid cycle environment in vivo

• Investigate dosing discrepancies:

  • Calculate effective concentrations reaching target tissues in vivo

  • Account for clearance and distribution factors absent in vitro

  • Adjust in vitro conditions to better match in vivo microenvironments

• Consider model-specific factors:

  • Evaluate species differences in LRAT structure and regulation

  • Assess differences between knockout models and naturally occurring mutations

  • Examine compensatory mechanisms present in vivo but absent in vitro

• Design bridging experiments:

  • Use ex vivo tissue explants as intermediate complexity models

  • Create 3D organoid cultures to better approximate in vivo conditions

  • Employ controlled release systems in vitro to mimic in vivo pharmacokinetics

• Statistical analysis approaches:

  • Employ meta-analysis techniques to identify patterns across datasets

  • Use Bayesian methods to incorporate prior knowledge into current analyses

  • Develop mathematical models that predict in vivo outcomes from in vitro data

What methodological approaches are most effective for evaluating the immune response to LRAT-VLPs in preclinical models?

To effectively evaluate immune responses to LRAT-VLPs:

• Humoral immunity assessment:

  • Measure anti-LRAT and anti-VLP antibody titers using ELISA

  • Characterize neutralizing antibodies through functional inhibition assays

  • Assess isotype distribution (IgG, IgM, IgA) to determine response type

• Cellular immunity evaluation:

  • Perform T-cell proliferation assays using LRAT peptides

  • Conduct ELISpot assays to enumerate cytokine-producing cells

  • Use flow cytometry to characterize T-cell activation markers

• Tissue-specific immune response:

  • Analyze ocular inflammation using clinical scoring systems

  • Perform histological examination for inflammatory cell infiltration

  • Measure cytokine levels in ocular fluids

• Long-term immunity monitoring:

  • Evaluate memory B and T cell responses after repeated administration

  • Assess cross-reactivity with endogenous LRAT

  • Monitor for delayed hypersensitivity reactions

• Immune tolerance strategies testing:

  • Evaluate the effectiveness of immunosuppressive regimens

  • Test tolerance induction protocols

  • Assess VLP surface modifications that reduce immunogenicity

How might the structural properties of LRAT inform the design of next-generation enzyme replacement therapies beyond VLP approaches?

The unique structural and functional properties of LRAT provide valuable insights for developing advanced enzyme replacement therapies:

• Structure-guided protein engineering:

  • Design stabilized LRAT variants that maintain the critical domain-swapping dimerization

  • Create fusion proteins that combine LRAT with cell-penetrating peptides

  • Develop hybrid enzymes incorporating the LRAT catalytic domain with targeting moieties

• Alternative delivery platforms:

  • Encapsulate LRAT in nanoparticles designed to target specific tissues

  • Develop liposomal formulations that mimic the native lipid environment of LRAT

  • Create hydrogel-based sustained release systems for localized delivery

• Catalytic enhancement approaches:

  • Engineer LRAT variants with improved catalytic efficiency based on understanding of the C161/H60 dyad mechanism

  • Develop allosteric activators that enhance LRAT function

  • Create chemical modifications that protect the catalytic cysteine from oxidation

• Combination therapies:

  • Design dual-function molecules that deliver both LRAT and its substrate retinol

  • Develop co-delivery systems for LRAT and RPE65 to restore the complete visual cycle

  • Create approaches that simultaneously address vitamin A delivery and esterification

What novel analytical approaches can address the challenges of distinguishing LRAT-VLP effects from those of endogenous LRAT in complex biological systems?

Novel analytical approaches to differentiate LRAT-VLP effects from endogenous LRAT include:

• Isotope labeling strategies:

  • Incorporate stable isotopes into recombinant LRAT for mass spectrometry tracking

  • Use deuterated retinol to track substrate utilization by different LRAT sources

  • Employ pulse-chase experiments with labeled precursors

• Genetic tagging approaches:

  • Develop LRAT variants with small epitope tags that don't affect function

  • Create CRISPR-edited cell lines with tagged endogenous LRAT

  • Use split-reporter systems to detect specific LRAT populations

• Advanced microscopy techniques:

  • Apply super-resolution microscopy to visualize spatial distribution of different LRAT populations

  • Use fluorescence correlation spectroscopy to measure diffusion properties

  • Employ FRET-based approaches to detect protein-protein interactions

• Single-cell analysis methods:

  • Develop single-cell proteomics approaches to detect LRAT variants

  • Use single-cell metabolomics to track retinyl ester formation

  • Apply trajectory inference methods to understand cellular responses

• Mathematical modeling approaches:

  • Develop kinetic models that distinguish contributions of different LRAT sources

  • Use Bayesian inference to estimate relative contributions to observed effects

  • Create multi-scale models that integrate molecular, cellular, and tissue-level data

What emerging technologies might enhance the study of LRAT-VLP interactions with the complex retinoid metabolism network?

Emerging technologies that could advance our understanding of LRAT-VLP interactions with retinoid metabolism include:

• Advanced spatial omics:

  • Spatial transcriptomics to map gene expression changes in response to LRAT-VLPs

  • Imaging mass spectrometry to visualize retinoid distribution in tissues

  • Spatial proteomics to map protein-protein interactions in their native context

• Organoid and microphysiological systems:

  • Retinal organoids with defined genetic backgrounds to study LRAT-VLP effects

  • Liver-eye microphysiological systems to study whole-body retinoid metabolism

  • Microfluidic devices that simulate retinoid transport between tissues

• In situ structural biology:

  • Cryo-electron tomography to visualize LRAT-VLPs in cellular environments

  • In-cell NMR to study LRAT conformational dynamics

  • Correlative light and electron microscopy to track both location and function

• Artificial intelligence approaches:

  • Machine learning algorithms to predict LRAT-VLP efficacy based on structural features

  • Network analysis tools to map the influence of LRAT-VLPs on retinoid metabolism

  • Predictive modeling of dynamic responses to therapeutic interventions

• Advanced genetic models:

  • Humanized animal models expressing human LRAT variants

  • Inducible and tissue-specific LRAT knockout/knockin systems

  • CRISPR-based screening to identify novel interactors with LRAT-VLPs

These emerging technologies, when applied to LRAT-VLP research, could significantly advance our understanding of complex retinoid metabolism and accelerate the development of targeted therapeutics for LRAT-associated diseases.